Revenue: FPH reported a 10% rise in revenue to $1.74 billion as growth returns to pre-Covid patterns.
Profit: Net profit after tax dropped 56% to $132.6 million after three abnormal items, while underlying profit rose 6% to $264.4m.
Key takeaway: The company is forecasting revenue for FY2025 of between $1.9 billion and $2 billion, net profit after tax of $310 million to $360m, and a lowered capital expenditure of around $150m. The assumption is based on a further improvement in gross margin based on historical pre-Covid levels.
It took 50 years for Fisher & Paykel Healthcare (FPH) to hit the milestone $1 billion revenue mark in 2019.
Five years later the respiratory healthcare company has given guidance of hitting close to double that – $1.9 billion to $2b in operating revenue for the 2025 financial year as growth rates
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Revenue: FPH reported a 10% rise in revenue to $1.74 billion as growth returns to pre-Covid patterns.
Profit: Net profit after tax dropped 56% to $132.6 million after three abnormal items, while underlying profit rose 6% to $264.4m.
Key takeaway: The company is forecasting revenue for FY2025 of between $1.9 billion and $2 billion, net profit after tax of $310 million to $360m, and a lowered capital expenditure of around $150m. The assumption is based on a further improvement in gross margin based on historical pre-Covid levels.
